Select octogenarians with stage IIIa non–small cell lung cancer can benefit from trimodality therapyCentral MessagePerspective by Andrew Tang, MD, MS, Andrew Feczko, MD, Sudish C. Murthy, MD, PhD, Siva Raja, MD, PhD, Alejandro Bribriesco, MD, Dean Schraufnagel, MD, Usman Ahmad, MD, Daniel P. Raymond, MD, Monisha Sudarshan, MD, MPH

Get full text

Morbidity and mortality after general surgery in heart and lung transplant patients by Alek Zywot, MD, MPH, Amber L. Turner, MPH, Joanna Sesti, MD, Russell C. Langan, MD, Andrew Nguyen, MD, Andreas R. de Biasi, MD, Siva Raja, MD, PhD, Usman Ahmad, MD, Subroto Paul, MD, MPH

Get full text

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC by Christopher A. Lemmon, MD, Gregory M.M. Videtic, MDCM, Sudish Murthy, MD, PhD, Kevin L. Stephans, MD, Marc Shapiro, MD, Usman Ahmad, MD, Daniel Raymond, MD, Vamsidhar Velcheti, MD, Alejandro Bribriesco, MD, Xuefei Jia, MS, James Stevenson, MD, Nathan A. Pennell, MD, PhD

Get full text

Adjuvant Therapy after Esophagectomy for Esophageal Cancer: Who Needs It?: Multi-institution Worldwide Observational Study by Siva Raja, MD, PhD, Thomas W. Rice, MD, Min Lu, PhD, Marie E. Semple, MPH, Andrew J. Toth, MS, Eugene H. Blackstone, MD, Sudish C. Murthy, MD, PhD, Usman Ahmad, MD, Michael McNamara, MD, Hemant Ishwaran, PhD, for the Worldwide Esophageal Cancer Collaboration Investigators

Get full text